MDMA-Assisted Therapy Shows Moderate-to-Large Benefits in Meta-Analysis

A systematic review of eight randomized trials finds MDMA-AT reduced psychopathology more than controls, but with high variability and poor harm reporting.

Evidence grade A · meta-analysis / systematic review. Here’s an honest read of what this study does — and doesn’t — show.

What the study found

Researchers found MDMA-assisted therapy was associated with a moderate-to-large incremental reduction in psychopathology compared to control conditions (effect size g = 1.03), with stronger effects against inert placebos than active controls. The effect was largest for trauma-related symptoms (g = 1.46) and smaller and non-significant for depression (g = 0.51). Only 23% of publications met high-quality standards for reporting harms.

Why it matters

The findings suggest researchers are exploring MDMA-AT as a potentially transdiagnostic intervention, but the gap between promising effect sizes and poor harm reporting transparency underscores why regulators and clinicians have called for larger, more rigorously conducted trials before drawing firm conclusions.

Sources

• ¶medRxiv

Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.